OUTLOOK

Although complement and even non-neutralizing Abs may contribute to control viral replication at several stages of the disease, HIV has developed mechanisms to turn complement-activation and opsonization to its advantage while avoiding CoML.

CONFLICT OF INTEREST STATEMENT

The authors declare that they have no conflict of interest.

ACKNOWLEDGMENT

The authors are supported by the 6^th frame work of the EU (DEC-VAC 2005-018685), grants of the Austrian Research Fund FWF (P18960 to DW and P17914 to HS) and the Federal Government of Tyrol (Tiroler Wissenschaftsfonds TWF-2008-1-562). The secretarial support of L. Hahn and Mag. B. Mullauer is gratefully acknowledged.

REFERENCES

[1] Azumi K, De Santis R, De Tomaso A, Rigoutsos I, Yoshizaki F, Pinto MR, et al. Genomic analysis of immunity in a Urochordate and the emergence of the vertebrate immune system: "waiting for Godot". Immunogenetics 2003; 55:570-81.

[2] He Y, Tang B, Zhang S, Liu Z, Zhao B, Chen L. Molecular and immunochemical demonstration of a novel member of Bf/C2 homolog in amphioxus Branchiostoma belcheri: implications for involvement of hepatic cecum in acute phase response. Fish Shellfish Immunol 2008; 24:768-78.

[3] Kimura A, Sakaguchi E, Nonaka M. Multi-component complement system of Cnidaria: C3, Bf, and MASP genes expressed in the endodermal tissues of a sea anemone, Nematostella vectensis. Immunobiology 2009; 214:165-78.

[4] Speth C, Prodinger WM, Wurzner R, Stoiber H, Dierich MP. In: Fundamental Immunology, Paul W E, Ed. Complement. Lippincott-Raven Publishers, PA. 2007; pp.1048-1078.

[5] Krych M, Molina H, Atkinson JP.

[6] Cohen JH, Atkinson JP, Klickstein LB, Oudin S, Subramanian VB, Moulds JM. The C3b∕C4b receptor (CR1, CD35) on erythrocytes: methods for study of the polymorphisms. Mol Immunol 1999; 36:819-25.

[7] Fearon DT, Carroll MC. Regulation of B lymphocyte responses to foreign and self-antigens by the CD19∕CD21 complex. Annu Rev Immunol 2000; 18:393-422.

[8] Cherukuri A, Cheng PC, Sohn HW, Pierce SK. The CD19∕CD21 complex functions to prolong B cell antigen receptor signaling from lipid rafts. Immunity 2001; 14:169-79.

[9] Dempsey PW, Allison ME, Akkaraju S, Goodnow CC, Fearon DT. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 1996; 271:348-350.

[10] Ehlers MR. Microbes Infect. 2000; 2:289-94.

[11] Diamond MS, Garcia-Aguilar J, Bickford JK, Corbi AL, Springer TA. The I domain is a major recognition site on the leukocyte integrin Mac-1 (CD11b∕CD18) for four distinct adhesion ligands. Cell Biol. 1993; 120:1031-43.

[12] Stoiber H, Banki Z, Wilflingseder D, Dierich MP. Complement-HIV interactions during all steps of viral pathogenesis. Vaccine 2008; 26:3046-54.

[13] Gerard C, Gerard NP. C5A anaphylatoxin and its seven transmembrane-segment receptor. Annu Rev Immunol. 1994; 12:775-808.

[14] Gerard C, Gerard NP. The chemotactic receptor for human C5a anaphylatoxin. Nature. 1991; 349:614-7.

[15] Crass T, Raffetseder U, Martin U, Grove M, Klos A, Kohl J, et al. Expression cloning of the human C3a anaphylatoxin receptor (C3aR) from differentiated U-937 cells. Eur J Immunol. 1996; 26:1944-50.

[16] Nataf S, Stahel PF, Davoust N, Barnum SR. Complement anaphylatoxin receptors on neurons: new tricks for old receptors? Trends Neurosci. 1999; 22:397-402.

[17] Zwirner J, Fayyazi A, Gotze O. Expression of the anaphylatoxin C5a receptor in non-myeloid cells. Mol Immunol. 1999; 36:877-84.

[18] Ebenbichler CF, Thielens NM, Vornhagen R, Marschang P, Arlaud GJ, Dierich MP.

[19] Spear GT, Jiang HX, Sullivan BL, Gewurz H, Landay AL, Lint TF. Direct binding of complement component C1q to human immunodeficiency virus (HIV) and human T lymphotrophic virus-I (HTLV-I) coinfected cells. AIDS Res Hum Retroviruses 1991; 7:579-585.

[20] Stoiber H, Clivio A, Dierich MP. Role of complement in HIV infection. Annu Rev Immunol 1997; 15:649-674.

[21] Prohaszka Z, Hidvegi T, Ujhelyi E, Stoiber H, Dierich MP, Susal C, et al. Interaction of complement and specific antibodies with the external glycoprotein (gp120) of human immunodeficiency virus type 1 (HIV-1). Immunology 1995; 85:184-189.

[22] Ji X, Gewurz H, Spear GT. Mannose binding lectin (MBL) and HIV. Mol Immunol. 2005; 42:145-52.

[23] Spear GT, Takefman DM, Sullivan BL, Landay AL, Zolla-Pazner S. Complement activation by human monoclonal antibodies to human immunodeficiency virus. J Virol 1993; 67: 53-9.

[24] Gregersen JP, Mehdi S, Baur A, Hilfenhaus J. Antibody- and complement-mediated lysis of HIV-infected cells and inhibition of viral replication. J Med Virol 1990; 30: 287-93.

[25] Aasa-Chapman MM, Holuigue S, Aubin K, Wong M, Jones NA, Cornforth D, et al. Detection of antibody­dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection. J Virol 2005; 79: 2823-30.

[26] Huber M, Fischer M, Misselwitz B, Manrique A, Kuster H, Niederost B, et al. Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection. PLoS Med 2006; 3: 441.

[27] Spear GT, Olinger GG, Saifuddin M, Gebel HM. Human antibodies to major histocompatibility complex alloantigens mediate lysis and neutralization of HIV-1 primary isolate virions in the presence of complement.

[28] Spear GT, Sullivan BL, Landay AL, Lint TF. Neutralization of human immunodeficiency virus type 1 by complement occurs by viral lysis. J Virol 1990; 64: 5869-73.

[29] Sullivan BL, Knopoff EJ, Saifuddin M, Takefman DM, Saarloos MN, Sha BE, et al. Susceptibility of HIV-1 plasma virus to complement-mediated lysis. Evidence for a role in clearance of virus in vivo. J Immunol 1996; 157: 1791-8.

[30] Dierich MP, Stoiber H, Clivio A. A “Complementary“ AIDS vaccine. Nature Med. 1996; 2:153-155.

[31] Banki Z, Soederholm A, Mullauer B, Dierich MP, Stoiber H. Tracing complement-retroviral interactions from mucosal surfaces to the lymphatic tissue. Front Biosci. 2007; 12:2096-2106.

[32] Frank I, Stoiber H, Godar S, Most J, Stockinger H, Dierich MP. Acquisition of host cell-surface-derived molecules by HIV-1. AIDS 1996; 10:1611-1620.

[33] Saifuddin M, Hedayati T, Atkinson JP, Holguin MH, Parker CJ, Spear GT. Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction. J Gen Virol 1997; 78: 1907-11.

[34] Marschang P, Sodroski J, Wurzner R, Dierich MP. Decay-accelerating factor (CD55) protects human immunodeficiency virus type 1 from inactivation by human complement. Eur J Immunol 1995; 25: 285-90.

[35] Montefiori DC, Cornell RJ, Zhou JY, Zhou JT, Hirsch VM, Johnson PR. Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection. Virology 1994; 205: 82-92.

[36] Stoiber H, Schneider R, Janatova J, Dierich MP. Human complement proteins C3b, C4b, factor H and properdin react with specific sites in gp120 and gp41, the envelope proteins of HIV-1. Immunobiology 1995; 193: 98-113.

[37] Stoiber H, Ebenbichler CF, Schneider R, Janatova J, Dierich MP. Interaction of several complement proteins with gp120 and gp41, the two envelope glycoproteins of HIV-1.

[38] Pinter C, Siccardi AG, Longhi R, Clivio A. Direct interaction of complement factor H with the C1 domain of HIV type 1 glycoprotein 120. AIDS Res Hum Retroviruses 1995; 11: 577-88.

[39] Pinter C, Siccardi AG, Lopalco L, Longhi R, Clivio A. HIV glycoprotein 41 and complement factor H interact with each other and share functional as well as antigenic homology. AIDS Res Hum Retroviruses 1995; 11: 971-80.

[40] Stoiber H, Pinter C, Siccardi AG, Clivio A, Dierich MP. Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55). J Exp Med 1996; 183: 307-10.

[41] Stoiber H, Ammann C, Spruth M, Mullauer B, Eberhart A, Harris CL, et al. Enhancement of complement-mediated lysis by a peptide derived from SCR13 of complement factor H. Immunobiology 2001; 203:670-686.

[42] Sullivan BL, Takefman DM, Spear GT. Complement can neutralize HIV-1 plasma virus by a C 5-independent mechanism. Virology 1998; 248, 173-81.

[43] Scherl M, Posch U, Obermoser G, Ammann C, Sepp N, Ulmer H, et al. Targeting human immunodeficiency virus type 1 with antibodies derived from patients with connective tissue disease. Lupus 2006; 15, 865-72.

[44] Nemerow GR, Cooper NR. Isolation of Epstein Barr-virus and studies of its neutralization by human IgG and complement. J Immunol 1981; 127, 272-278.

[45] Rabinovitch M. Professional and non-professional phagocytes: an introduction. Trends Cell Biol 1995; 5: 85-7.

[46] Brown EJ. Complement receptors and phagocytosis. Curr Opin Immunol 1991; 3: 76-82.

[47] Kedzierska K, Azzam R, Ellery P, Mak J, Jaworowski A, Crowe SM. Defective phagocytosis by human monocyte/macrophages following HIV-1 infection: underlying mechanisms and modulation by adjunctive cytokine therapy. J Clin Virol 2003; 26: 247.

[48] Bender BS, Davidson BL, Kline R, Brown C, Quinn TC. Role of the mononuclear phagocyte system in the immunopathogenesis of human immunodeficiency virus infection and the acquired immunodeficiency syndrome.

[49] Monari C, Casadevall A, Pietrella D, Bistoni F, Vecchiarelli A. Neutrophils from patients with advanced human immunodeficiency virus infection have impaired complement receptor function and preserved Fcgamma receptor function. J Infect Dis 1999; 180: 1542-9.

[50] Thomas CA, Weinberger OK, Ziegler BL, Greenberg S, Schieren I, Silverstein SC, et al. Human immunodeficiency virus-1 env impairs Fc receptor-mediated phagocytosis via a cyclic adenosine monophosphate­dependent mechanism. Blood 1997; 90:3760-5.

[51] Azzam R, Kedzierska K, Leeansyah E, Chan H, Doischer D, Gorry PR, et al. Impaired complement-mediated phagocytosis by HIV type-1-infected human monocyte-derived macrophages involves a cAMP-dependent mechanism. AIDS Res Hum Retroviruses 2006; 22:619-29.

[52] Beck Z, Prohaszka Z, Fust G. Traitors of the immune system-enhancing antibodies in HIV infection: their possible implication in HIV vaccine development. Vaccine 2008 ; 26:3078-85.

[53] Freissmuth D, Dierich MP, Stoiber H. Role of complement in the pathogenesis of SIV infection. Front Biosci. 2003; 8:733-9.

[54] Banki Z, Stoiber H, Dierich MP. HIV and human complement: inefficient virolysis and effective adherence. Immunol Lett., 2005; 97:209-214.

[55] Willey S, Aasa-Chapman MM. Humoral immunity to HIV-1: neutralisation and antibody effector functions. Trends Microbiol. 2008; 16:596-604.

[56] Huber M, Trkola A. Humoral immunity to HIV-1: neutralization and beyond. J Intern Med. 2007; 262:5-25.

[57] Mouhoub A, Delibrias CC, Fischer E, Boyer V, Kazatchkine MD. Ligation of CR1 (C3b receptor, CD35) on CD4+ T lymphocytes enhances viral replication in HIV-infected cells. Clin Exp Immunol. 1996; 106:297-303.

[58] June RA, Schade SZ, Bankowski MJ, Kuhns M, McNamara A, Lint TF, et al. Complement and antibody mediate enhancement of HIV infection by increasing virus binding and provirus formation. AIDS 1991; 5:269-74.

[59] Zhou J, Montefiori DC. Complement-activating antibodies in sera from infected individuals and vaccinated volunteers that target human immunodeficiency virus type 1 to complement receptor type 1 (CR1, CD35). Virology 1996; 226:13-21.

[60] Robinson WE Jr, Montefiori DC, Mitchell WM. Complement-mediated antibody-dependent enhancement of HIV-1 infection requires CD4 and complement receptors. Virology 1990; 175:600-4.

[61] Robinson WE Jr, Montefiori DC, Mitchell WM. Antibody-dependent enhancement of human immunodeficiency virus type 1 infection. Lancet 1988; 1: 790-4.

[62] Gras GS, Dormont D. Antibody-dependent and antibody-independent complement-mediated enhancement of human immunodeficiency virus type 1 infection in a human, Epstein-Barr virus-transformed B-lymphocytic cell line. J Virol. 1991; 65:541-5.

[63] Tremblay M, Meloche S, Sekaly RP, Wainberg MA. Complement receptor 2 mediates enhancement of human immunodeficiency virus 1 infection in Epstein-Barr virus-carrying B cells. J Exp Med. 1990; 171:1791-6.

[64] Gras G, Richard Y, Roques P, Olivier R, Dormont D. Complement and virus-specific antibody-dependent infection of normal B lymphocytes by human immunodeficiency virus type 1. Blood 1993; 81:1808-18.

[65] Delibrias CC, Mouhoub A, Fischer E, Kazatchkine MD. CR1(CD35) and CR2(CD21) complement C3 receptors are expressed on normal human thymocytes and mediate infection of thymocytes with opsonized human immunodeficiency virus. Eur J Immunol. 1994; 24:2784-8.

[66] Toth FD, Mosborg-Petersen P, Kiss J, Aboagye-Mathiesen G, Zdravkovic M, Hager H, et al. Antibody-dependent enhancement of HIV-1 infection in human term syncytiotrophoblast cells cultured in vitro. Clin Exp Immunol. 1994; 96:389-94.

[67] Boyer V, Delibrias C, Noraz N, Fischer E, Kazatchkine MD, Desgranges C. Complement receptor type 2 mediates infection of the human CD4-negative Raji B-cell line with opsonized HIV. Scand J Immunol. 1992 ; 36:879-83.

[68] Boyer V, Desgranges C, Trabaud MA, Fischer E, Kazatchkine MD. Complement mediates human immunodeficiency virus type 1 infection of a human T cell line in a CD4- and antibody-independent fashion. J Exp Med. 1991; 173:1151-8.

[69] Pruenster M, Wilflingseder D, Banki Z, Ammann CG, Muellauer B, Meyer M, et al. C-type lectin-independent interaction of complement opsonized HIV with monocyte-derived dendritic cells. Eur J Immunol. 2005; 35:2691-8.

[70] Rizzuto CD, Sodroski JG. Contribution of virion ICAM-1 to human immunodeficiency virus infectivity and sensitivity to neutralization. J Virol. 1997; 71:4847-51.

[71] Stoiber H, Frank I, Spruth M, Schwendinger M, Mullauer B, Windisch JM, et al. Inhibition of HIV-1 infection in vitro by monoclonal antibodies to the complement receptor type 3 (CR3): an accessory role for CR3 during virus entry? Mol Immunol. 1997; 34:855-63.

[72] Thieblemont N, Haeffner-Cavaillon N, Haeffner A, Cholley B, Weiss L, Kazatchkine MD. Triggering of complement receptors CR1 (CD35) and CR3 (CD11b∕CD18) induces nuclear translocation of NF-kappa B (p50∕p65) in human monocytes and enhances viral replication in HIV-infected monocytic cells. J Immunol. 1995; 155:4861-7.

[73] Kacani L, Frank I, Spruth M, Schwendinger MG, Mullauer B, Sprinzl GM, et al. Dendritic cells transmit human immunodeficiency virus type 1 to monocytes and monocyte-derived macrophages. J Virol. 1998; 72:6671-7.

[74] Hussain LA, Kelly CG, Rodin A, Jourdan M, Lehner T. Investigation of the complement receptor 3 (CD11b∕CD18) in human rectal epithelium. Clin Exp Immunol. 1995; 102:384-8.

[75] Wilflingseder D, Banki Z, Garcia E, Pruenster M, Pfister G, Muellauer B, et al. gG opsonization of HIV impedes provirus formation in and infection of dendritic cells and subsequent long-term transfer to T cells. J Immunol. 2007; 178:7840-8.

[76] Hess C, Klimkait T, Schlapbach L, Del Zenero V, Sadallah S, Horakova E, et al. Association of a pool of HIV-1 with erythrocytes in vivo: a cohort study. Lancet 2002; 359: 2230-2234.

[77] Horakova E, Gasser O, Sadallah S, Inal JM, Bourgeois G, Ziekau I, et al. Complement mediates the binding of HIV to erythrocytes. J. Immunol. 2004; 173: 4236-4241.

[78] Banki Z, Wilflingseder D, Ammann CG, Pruenster M, Mullauer B, Hollander K, et al. Factor I-mediated processing of complement-fragments on HIV immune-complexes targets HIV to CR2-expressing B cells and facilitates B cell-mediated transmission of opsonized HIV to T cells. J Immunol. 2006; 177:3469-76.

[79] Moir S, Malaspina A, Li Y, Chun TW, Lowe T, Adelsberger J, et al. B cells of HIV-1-infected patients bind virions through CD21-complement interactions and transmit infectious virus to activated T cells. J Exp Med. 2000; 192:637-46.

[80] Joling P, Bakker LJ, Van Strijp JA, Meerloo T, de Graaf L, Dekker ME, et al. Binding of human immunodeficiency virus type-1 to follicular dendritic cells in vitro is complement dependent. J. Immunol. 1993; 150: 1065-1073.

[81] Kacani L, Prodinger WM, Sprinzl GM, Schwendinger MG, M. Spruth, H. Stoiber, et al. Detachment of human immunodeficiency virus type 1 from germinal centers by blocking complement receptor type 2. J Virol. 2000; 74: 7997-8002.

[82] Banki Z, Kacani L, Rusert P, Pruenster M, Wilflingseder D, Falkensammer B, et al. Complement dependent trapping of infectious HIV in human lymphoid tissues. AIDS 2005; 19: 481-486.

[83] Pantaleo G, Fauci AS. Immunopathogenesis of HIV infection. Annu. Rev. Microbiol. 1996; 50: 825-854.

[84] Haase AT, Henry K, Zupancic M, Sedgewick G, Faust RA, Melroe H, et al. Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science 1996; 274: 985-989.

[85] Stingl G, Wolff-Schreiner EC, Pichler WJ, Gschnait F, Knapp W, Wolff K. Epidermal Langerhans cells bear Fc and C3 receptors. Nature 1977; 268: 245-246.

[86] Smith-Franklin BA, Keele BF, Tew JG, Gartner S, Szakal AK, Estes JD, et al. Follicular dendritic cells and the persistence of HIV infectivity: the role of antibodies and Fcgamma receptors. J. Immunol. 2002; 168: 2408-2414.

[87] Chakrabarti L, Cumont MC, Montagnier L, Hurtrel B. Kinetics of primary SIV infection in lymph nodes. J. Med. Primatol. 1994; 23: 117-1124.

[88] Hurtrel B, Chakrabarti L, Hurtrel M, Bach JM, Ganiere JP, Montagnier L. Early events in lymph nodes during infection with SIV and FIV. Res. Virol. 1994 ; 145 : 221-227.

[89] Stahl-Hennig C, Steinman RM, Tenner-Racz K, Pope M, Stolte N, Matz-Rensing K, et al. Rapid infection of oral mucosal-associated lymphoid tissue with simian immunodeficiency virus. Science 1999; 285: 1261-1265.

[90] Milush JM, Kosub D, Marthas M, Schmidt K, Scott F, Wozniakowski A, et al. Rapid dissemination of SIV following oral inoculation. AIDS 2004; 18: 2371-2380.

[91] Stoiber H, Prunster M, Ammann CG, Dierich MP. Complement- opsonized HIV: the free rider on its way to infection. Mol. Immunol. 2005; 42:153-160.

[92] Heath SL, Tew JG, Szakal AK Burton GF. Follicular dendritic cells and human immunodeficiency virus infectivity. Nature 1995; 377: 740-744.

[93] Cavert W, Notermans DW, Staskus K, Wietgrefe SW, Zupancic M, Gebhard K, et al. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 1997; 276: 960-964.

[94] Fujiwara M, Tsunoda R, Shigeta S, Yokota T, Baba M. Human follicular dendritic cells remain uninfected and capture human immunodeficiency virus type 1 through CD54-CD11a interaction. J. Virol. 1999; 73: 3603-3607.

[95] Jakubik JJ, Saifuddin M, Takefman DM, Spear GT. B lymphocytes in lymph nodes and peripheral blood are important for binding immune complexes containing HIV-1. Immunology 1999; 96: 612-619.

[96] Doepper S, Stoiber H, Kacani L, Sprinzl G, Steindl F, Prodinger WM, et al. B cell-mediated infection of stimulated and unstimulated autologous T lymphocytes with HIV-1: role of complement. Immunobiology 2000; 202; 293-305.

[97] Jakubik JJ, Saifuddin M, Takefman DM, Spear GT. Immune complexes containing human immunodeficiency virus type 1 primary isolates bind to lymphoid tissue B lymphocytes and are infectious for T lymphocytes. J. Virol. 2000; 74: 552-555.

[98] Dopper S, Wilflingseder D, Prodinger WM, Stiegler G, Speth C, Dierich MP, et al. Mechanism(s) promoting HIV- 1 infection of primary unstimulated T lymphocytes in autologous B cell/T cell co-cultures. Eur J Immunol. 2003; 33: 2098-2107.

[99] Reid DM, Perry VH, Andersson PB, Gordon S. Mitosis and apoptosis of microglia in vivo induced by an anti-CR3 antibody which crosses the blood-brain barrier. Neuroscience. 1993; 56:529-33.

[100] Bruder C, Hagleitner M, Darlington G, Mohsenipour I, Wurzner R, Hollmuller I, et al. HIV-1 induces complement factor C3 synthesis in astrocytes and neurons by modulation of promoter activity. Mol Immunol. 2004; 40:949-61.

[101] Speth C, Schabetsberger T, Mohsenipour I, Stockl G, Wurzner R, Stoiber H, et al. Mechanism of human immunodeficiency virus-induced complement expression in astrocytes and neurons. J Virol. 2002; 76:3179-88.

[102] Fearon DT. Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte. J. Exp. Med. 1980; 152: 20-30.

[103] Paccaud JP, Carpentier JL, Schifferli JA. Direct evidence for the clustered nature of complement receptors type 1 on the erythrocyte membrane. J. Immunol. 1988; 141: 3889-3894.

[104] Monari C, Casadevall A, Pietrella D, Bistoni F, Vecchiarelli A. Neutrophils from patients with advanced human immunodeficiency virus infection have impaired complement receptor function and preserved Fcgamma receptor function. J Infect Dis. 1999; 180:1542-9.

[105] Wahl SM, Allen JB, Gartner S, Orenstein JM, Popovic M, Chenoweth DE, et al. HIV-1 and its envelope glycoprotein down-regulate chemotactic ligand receptors and chemotactic function of peripheral blood monocytes. J Immunol. 1989; 142:3553-9.

[106] Kacani L, Banki Z, Zwirner J, Schennach H, Bajtay Z, Erdei A, et al. C5a and C5a(desArg) enhance the susceptibility of monocyte-derived macrophages to HIV infection. J Immunol. 2001; 166:3410-5.

[107] Soederholm A, Banki Z, Wilflingseder D, Gassner C, Zwirner J, Lopez-Trascasa M, et al. HIV-1 induced generation of C5a attracts immature dendriticcells and promotes infection of autologous T cells. Eur J Immunol. 2007; 37:2156-63.

[108] Wasserheit JN. HIV infection and other STDs: so close and yet so far. Sex Transm Dis. 1999; 26:549-50.